In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy

Cancer Research

Volumn 71, Issue 8, 2011, Pages 2871-2881

  Lee, James C ^a,d   Hayman, Erik ^a,b   Pegram, Hollie J ^a,b   Santos, Elmer ^b   Heller, Glenn ^b   Sadelain, Michel ^a,b,c   Brentjens, Renier ^a,b,c,d  

^a Center for Cell Engineering   (United States)

^b Department of Medicine ^*  (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CYCLOPHOSPHAMIDE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURKITT LYMPHOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAJI CELL; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD19; BURKITT LYMPHOMA; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, SCID; NIH 3T3 CELLS; RECEPTORS, ANTIGEN; RETROVIRIDAE; T-LYMPHOCYTES, REGULATORY; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79954573204     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0552     Document Type: Article

References (47)

1. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3:35-45. (Pubitemid 37328885)
2. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9:279-86. (Pubitemid 36362782)
3. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13:5426-35. (Pubitemid 47510370)
4. Cheadle EJ, Gilham DE, Hawkins RE. The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br J Haematol 2008;142:65-8. (Pubitemid 351783147)
5. James SE, Orgun NN, Tedder TF, Shlomchik MJ, Jensen MC, Lin Y, et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 2009;114:5454-63.
6. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9. (Pubitemid 44547756)
7. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al.Aphase I study on adoptive immunotherapy using genemodified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-15. (Pubitemid 44703776)
8. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20- specific T cells. Blood 2008;112:2261-71.
9. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cellsuppressive activity. Blood 2008;111:4233-44.
10. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;213:131-45. (Pubitemid 44401498)
11. +) T cells. Gastroenterology 2008;135:234-43. (Pubitemid 351899008)
12. + T reg cells. J Exp Med 2006;203:1701-11. (Pubitemid 44036276)
13. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52. (Pubitemid 41716771)
14. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998;160:1212-8. (Pubitemid 28093417)
15. + T cells. Curr Opin Immunol 2003;15:690-6. (Pubitemid 37434077)
16. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-65. (Pubitemid 46919862)
17. +) immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoidinduced TNF receptor. Immunity 2002;16:311-23. (Pubitemid 34211969)
18. +) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302. (Pubitemid 30470312)
19. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108: 804-11. (Pubitemid 44154611)
20. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12. (Pubitemid 36182591)
21. +) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006;66:10145-52. (Pubitemid 44672069)
22. Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, et al. Treg depletion inhibits efficacy of cancer immunotherapy: Implications for clinical trials. PLoS ONE 2008;3:e1983.
23. Miyara M, Sakaguchi S. Natural regulatory T cells: Mechanisms of suppression. Trends Mol Med 2007;13:108-16. (Pubitemid 46341958)
24. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-76.
25. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008;6:12.
26. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57. (Pubitemid 46218728)
27. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, et al. Increased intensity lymphodepletion and adoptive immunotherapy- how far can we go?Nat Clin Pract Oncol 2006;3:668-81. (Pubitemid 44843125)
28. + regulatory T cells with potent suppressor activity. J Immunol Methods 2006;315:27-36. (Pubitemid 44429953)
29. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006;177:8338-47. (Pubitemid 44893795)
30. + regulatory T cells cultured with rapamycin. J Immunol 2007;178:320-9. (Pubitemid 46033615)
31. Gong MC, Latouche JB, Krause A, Heston WDW, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999;1:123-7.
32. +regulatory T cells. Blood 2005;105: 4743-8. (Pubitemid 40807298)
33. Oberg HH, Wesch D, Lenke J, Kabelitz D. An optimized method for the functional analysis of human regulatory T cells. Scand J Immunol 2006;64:353-60. (Pubitemid 44215126)
34. Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, Punzalan B, et al. Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med 2009;15:338-44.
35. + naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998;10: 1969-80. (Pubitemid 28566059)
36. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-96. (Pubitemid 28357757)
37. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008;333:167-79.
38. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982;155:1063-74. (Pubitemid 12142723)
39. + suppressor- inducer T-cells. Cancer Res 1988;48:1671-5. (Pubitemid 18091225)
40. + CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018-25. (Pubitemid 41291715)
41. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008;68:5439-49.
42. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006;20:1819-28. (Pubitemid 44574993)
43. + Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol 2009;39:3091-6.
44. + T cell suppressor function. Eur J Immunol 2004;34:366-76. (Pubitemid 39255947)
45. Koenecke C, Ukena SN, Ganser A, Franzke A. Regulatory T cells as therapeutic target in Hodgkin's lymphoma. Expert Opin Ther Targets 2008;12:769-82. (Pubitemid 351877305)
46. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44. (Pubitemid 39255944)
47. +Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J Clin Invest 2008;118:3751-61.